AlloVir to wind down PhI­II tri­als for fu­til­i­ty and will re­view strate­gic al­ter­na­tives

AlloVir is pon­der­ing its cor­po­rate fu­ture af­ter find­ing out that its lead an­tivi­ral cell ther­a­py can­di­date is like­ly in­ef­fec­tive.

The biotech had been test­ing posoleu­cel, an off-the-shelf virus-spe­cif­ic T cell ther­a­py, in three sep­a­rate Phase III tri­als. At the pre-planned fu­til­i­ty analy­ses, all three in­de­pen­dent da­ta safe­ty mon­i­tor­ing boards (DSMBs) rec­om­mend­ed stop­ping the re­spec­tive tri­als they were over­see­ing, all say­ing that da­ta sug­gest­ed the stud­ies were un­like­ly to meet their pri­ma­ry end­points.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER